Clinical significance of ascites in epithelial ovarian cancer

Neoplasma

Volumn 60, Issue 5, 2013, Pages 546-552

  Huang, H ^a   Li, Y J ^a   Lan, C Y ^a   Huang, Q D ^a   Feng, Y L ^a   Huang, Y W ^a   Liu, J H ^a  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

Author keywords

Ascites; Epithelial ovarian cancer; Prognosis

Indexed keywords

ADULT; AGED; ARTICLE; ASCITES FLUID; ASCITES TUMOR; CANCER PROGNOSIS; CANCER STAGING; FEMALE; HISTOLOGY; HUMAN; INCIDENCE; LAPAROTOMY; MAJOR CLINICAL STUDY; METASTASIS; OVARY CARCINOMA; SURVIVAL RATE; TUMOR VOLUME; ASCITES; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; NEOPLASM; OVARY TUMOR; PATHOLOGY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL;

ADULT; AGED; ASCITES; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; NEOPLASM STAGING; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS;

EID: 84891942510     PISSN: 00282685     EISSN: 13384317     Source Type: Journal    
DOI: 10.4149/neo_2013_071     Document Type: Article

References (25)

1. BEREK JS, HACKER NF. Berek & Hacker's gynecologic oncology, 5th edition. Wolters Kluwer/Lippincott Williams & Wilkins Health, Philadelphia: 895, 2010.
2. JACOBS IJ, MENON U. Progress and challenges in screening for early detection of ovarian cancer. Mol Cell Proteomics 2004; 3: 355-366. http://dx.doi.org/10.1074/mcp.R400006-MCP200
3. FLAM F, EINHORN N, SJOVALL K. Symptomatology of ovarian cancer: Eur J Obstet Gynecol Reprod Biol 1988; 27: 53-57. http://dx.doi.org/10.1016/S0028-2243(88)80010-8
4. BONNEFOI H, A'HERN RP, FISHER C, MACFARLANE V, BARTON D et al. Natural history of stage IV epithelial ovarian cancer. J Clin Oncol 1999; 17, 767-775.
5. AYANTUNDE AA, PARSONS SL. Pattern and prognostic factors in patients with malignant ascites: a retrospective study. Ann Oncol 2007; 18: 945-949. http://dx.doi.org/10.1093/annonc/mdl499
6. DEMBO AJ, DAVY M, STENWIG AE, BERLE EJ, BUSH RS et al. Prognostic factors in patients with stage I epithelial ovarian cancer. Obstet Gynecol 1990; 75: 263-273.
7. PULS LE, DUNIHO T, HUNTER JE, KRYSCIO R, BLACKHURST D et al. The prognostic implication of ascites in advanced-stage ovarian cancer. Gynecol Oncol 1996; 61: 109-112. http://dx.doi.org/10.1006/gyno.1996.0106
8. PARSONS SL, LANG MW, STEELE RJ. Malignant ascites: a 2-year review from a teaching hospital. Eur J Surg Oncol 1996; 22: 237-239. http://dx.doi.org/10.1016/S0748-7983(96)80009-6
9. AYHAN A, GULTEKIN M, TASKIRAN C, DURSUN P, FIRAT P et al. Ascites and epithelial ovarian cancers: a reappraisal with respect to different aspects. Int J Gynecol Cancer 2007; 17: 68-75. http://dx.doi.org/10.1111/j.1525-1438.2006.00777.x
10. MIRONOV O, ISHILL NM, MIRONOV S, VARGAS HA, ZHENG J et al. Pleural effusion detected at CT prior to primary cytoreduction for stage III or IV ovarian carcinoma: effect on survival. Radiology 2011; 258: 776-784. http://dx.doi.org/10.1148/radiol.10100162
11. WILAILAK S, LINASMITA V, SRIVANNABOON S. Malignant ascites in female patients: a seven-year review. J Med Assoc Thai 1999; 82: 15-19.
12. BECKER G, GALANDI D, BLUM HE. Malignant ascites: systematic review and guideline for treatment. Eur J Cancer 2006; 42: 589-597. http://dx.doi.org/10.1016/j.ejca.2005.11.018
13. MACKEY JR, VENNER PM. Malignant ascites: demographics, therapeutic efficacy and predictors of survival. Can J Oncol 1996; 6: 474-480.
14. MAKAR AP, BAEKELANDT M, TROPE CG, KRISTENSEN GB. The prognostic significance of residual disease, FIGO substage, tumor histology, and grade in patients with FIGO stage III ovarian cancer. Gynecol Oncol 1995; 56: 175-180. http://dx.doi.org/10.1006/gyno.1995.1027
15. OMURA GA, BRADY MF, HOMESLEY HD, YORDAN E, MAJOR FJ et al. Long-term follow-up and prognostic factor analysis in advanced ovarian carcinoma: the Gynecologic Oncology Group experience. J Clin Oncol 1991; 9: 1138-1150.
16. SORBE B, FRANKENDAL B. Prognostic importance of ascites in ovarian carcinoma. Acta Obstet Gynecol Scand 1983; 62: 415-418. http://dx.doi.org/10.3109/00016348309154212
17. FELDMAN GB, KNAPP RC, ORDER SE, HELLMAN S. The role of lymphatic obstruction in the formation of ascites in a murine ovarian carcinoma. Cancer Res 1972; 32: 1663-1666.
18. FANG X, YU S, BAST RC, LIU S, XU HJ et al. Mechanisms for lysophosphatidic acid-induced cytokine production in ovarian cancer cells. J Biol Chem 2004; 279: 9653-9661. http://dx.doi.org/10.1074/jbc.M306662200
19. LEE HK, CHAE HS, KIM JS, KIM HK, CHO YS et al. Vascular endothelial growth factor levels in ascites between chemonaive and chemotreated patients. Yonsei Med J 2008; 49: 429-435. http://dx.doi.org/10.3349/ymj.2008.49.3.429
20. BELOTTI D, PAGANONI P, MANENTI L, GAROFALO A, MARCHINI S et al. Matrix metalloproteinases (MMP9 and MMP2) induce the release of vascular endothelial growth factor (VEGF) by ovarian carcinoma cells: implications for ascites formation. Cancer Res 2003; 63: 5224-5229.
21. ZUCKERMAN E, LANIR A, SABO E, ROSENVALDZUCKERMAN T, MATTER I et al. Cancer antigen 125: a sensitive marker of ascites in patients with liver cirrhosis. Am J Gastroenterol 1999; 94: 1613-1618. http://dx.doi.org/10.1111/j.1572-0241.1999.01152.x
22. ADACHI S, NODA T, KIYOZUKA Y, ITO K, ITANI Y et al. The importance of CA125 immunohistochemical staining in patients with ovarian cancer. Nihon Sanka Fujinka Gakkai Zasshi 1994; 46: 896-902.
23. BURLESON KM, CASEY RC, SKUBITZ KM, PAMBUCCIAN SE, OEGEMA TJ et al. Ovarian carcinoma ascites spheroids adhere to extracellular matrix components and mesothelial cell monolayers. Gynecol Oncol 2004; 93: 170-181. http://dx.doi.org/10.1016/j.ygyno.2003.12.034
24. VERGOTE I, DE BRABANTER J, FYLES A, BERTELSEN K, EINHORN N et al. Prognostic importance of degree of differentiation and cyst rupture in stage I invasive epithelial ovarian carcinoma. Lancet 2001; 357: 176-182. http://dx.doi.org/10.1016/S0140-6736(00)03590-X
25. VON GRUENIGEN VE, FRASURE HE, REIDY AM, GIL KM. Clinical disease course during the last year in ovarian cancer. Gynecol Oncol 2003; 90: 619-624. http://dx.doi.org/10.1016/S0090-8258(03)00418-9